Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

June 1, 2024

https://www.globenewswire.com/news-release/2024/06/01/2891828/0/en/Affimed-Provides-Follow-up-Data-of-AFM24-plus-Atezolizumab-Showing-Durable-Responses-in-Heavily-Pretreated-NSCLC-EGFR-Wild-type-Patients-and-Positive-Initial-Data-from-the-NSCLC-EG.html

MANNHEIM, Germany, June 01, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.